FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2010426521> ?p ?o ?g. }

• W2010426521 endingPage "e106891" @default.
• W2010426521 startingPage "e106891" @default.
• W2010426521 abstract "Classical swine fever virus (CSFV) is the causative agent of classical swine fever (CSF), which is a highly contagious swine disease that causes significant economic loses to the pig industry worldwide. The envelope E2 glycoprotein of CSFV is the most important viral antigen in inducing protective immune response against CSF. In this study, we generated a mammalian cell clone (BCSFV-E2) that could stably produce a secreted form of CSFV E2 protein (mE2). The mE2 protein was shown to be N-linked glycosylated and formed a homodimer. The vaccine efficacy of mE2 was evaluated by immunizing pigs. Twenty-five 6-week-old Landrace piglets were randomly divided into five groups. Four groups were intramuscularly immunized with mE2 emulsified in different adjuvants twice at four-week intervals. One group was used as the control group. All mE2-vaccinated pigs developed CSFV-neutralizing antibodies two weeks after the first vaccination with neutralizing antibody titers ranging from 1∶40 to 1∶320. Two weeks after the booster vaccination, the neutralizing antibody titers increased greatly and ranged from 1∶10,240 to 1∶81,920. At 28 weeks after the booster vaccine was administered, the neutralizing antibody titers ranged from 1∶80 to 1∶10240. At 32 weeks after the first vaccination, pigs in all the groups were challenged with a virulent CSFV strain at a dose of 1×105 TCID50. At two weeks after the challenge, all the mE2-immunized pigs survived and exhibited no obvious symptoms of CSF. The neutralizing antibody titer at this time was 20,480. Unvaccinated pigs in the control group exhibited symptoms of CSF 3–4 days after challenge and were euthanized from 7–9 days after challenge when the pigs became moribund. These results indicate that the mE2 is a good candidate for the development of a safe and effective CSFV subunit vaccine." @default.
• W2010426521 created "2016-06-24" @default.
• W2010426521 creator A5002273831 @default.
• W2010426521 creator A5005169752 @default.
• W2010426521 creator A5008960660 @default.
• W2010426521 creator A5031465676 @default.
• W2010426521 creator A5039037064 @default.
• W2010426521 creator A5045956012 @default.
• W2010426521 creator A5065503231 @default.
• W2010426521 creator A5081155699 @default.
• W2010426521 creator A5091074641 @default.
• W2010426521 date "2014-09-08" @default.
• W2010426521 modified "2023-09-25" @default.
• W2010426521 title "Generation and Efficacy Evaluation of Recombinant Classical Swine Fever Virus E2 Glycoprotein Expressed in Stable Transgenic Mammalian Cell Line" @default.
• W2010426521 cites W1563780305 @default.
• W2010426521 cites W1983314022 @default.
• W2010426521 cites W1989609219 @default.
• W2010426521 cites W1993150775 @default.
• W2010426521 cites W1993658549 @default.
• W2010426521 cites W1994148199 @default.
• W2010426521 cites W2005298446 @default.
• W2010426521 cites W2005706396 @default.
• W2010426521 cites W2019425552 @default.
• W2010426521 cites W2027809784 @default.
• W2010426521 cites W2031964159 @default.
• W2010426521 cites W2057655039 @default.
• W2010426521 cites W2059691183 @default.
• W2010426521 cites W2071186316 @default.
• W2010426521 cites W2071875823 @default.
• W2010426521 cites W2073233589 @default.
• W2010426521 cites W2079854374 @default.
• W2010426521 cites W2093365802 @default.
• W2010426521 cites W2094068823 @default.
• W2010426521 cites W2102093325 @default.
• W2010426521 cites W2106090606 @default.
• W2010426521 cites W2108111669 @default.
• W2010426521 cites W2108827586 @default.
• W2010426521 cites W2113995037 @default.
• W2010426521 cites W2126192775 @default.
• W2010426521 cites W2127136000 @default.
• W2010426521 cites W2130572630 @default.
• W2010426521 cites W2130576733 @default.
• W2010426521 cites W2140211977 @default.
• W2010426521 cites W2147073036 @default.
• W2010426521 cites W2161199223 @default.
• W2010426521 cites W2165802537 @default.
• W2010426521 doi "https://doi.org/10.1371/journal.pone.0106891" @default.
• W2010426521 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4157854" @default.
• W2010426521 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25198669" @default.
• W2010426521 hasPublicationYear "2014" @default.
• W2010426521 type Work @default.
• W2010426521 sameAs 2010426521 @default.
• W2010426521 citedByCount "20" @default.
• W2010426521 countsByYear W20104265212016 @default.
• W2010426521 countsByYear W20104265212017 @default.
• W2010426521 countsByYear W20104265212018 @default.
• W2010426521 countsByYear W20104265212019 @default.
• W2010426521 countsByYear W20104265212020 @default.
• W2010426521 countsByYear W20104265212021 @default.
• W2010426521 countsByYear W20104265212023 @default.
• W2010426521 crossrefType "journal-article" @default.
• W2010426521 hasAuthorship W2010426521A5002273831 @default.
• W2010426521 hasAuthorship W2010426521A5005169752 @default.
• W2010426521 hasAuthorship W2010426521A5008960660 @default.
• W2010426521 hasAuthorship W2010426521A5031465676 @default.
• W2010426521 hasAuthorship W2010426521A5039037064 @default.
• W2010426521 hasAuthorship W2010426521A5045956012 @default.
• W2010426521 hasAuthorship W2010426521A5065503231 @default.
• W2010426521 hasAuthorship W2010426521A5081155699 @default.
• W2010426521 hasAuthorship W2010426521A5091074641 @default.
• W2010426521 hasBestOaLocation W20104265211 @default.
• W2010426521 hasConcept C12590561 @default.
• W2010426521 hasConcept C159047783 @default.
• W2010426521 hasConcept C159654299 @default.
• W2010426521 hasConcept C203014093 @default.
• W2010426521 hasConcept C22070199 @default.
• W2010426521 hasConcept C22889606 @default.
• W2010426521 hasConcept C2522874641 @default.
• W2010426521 hasConcept C2779005923 @default.
• W2010426521 hasConcept C2779261636 @default.
• W2010426521 hasConcept C32611913 @default.
• W2010426521 hasConcept C71924100 @default.
• W2010426521 hasConcept C86803240 @default.
• W2010426521 hasConcept C8891405 @default.
• W2010426521 hasConceptScore W2010426521C12590561 @default.
• W2010426521 hasConceptScore W2010426521C159047783 @default.
• W2010426521 hasConceptScore W2010426521C159654299 @default.
• W2010426521 hasConceptScore W2010426521C203014093 @default.
• W2010426521 hasConceptScore W2010426521C22070199 @default.
• W2010426521 hasConceptScore W2010426521C22889606 @default.
• W2010426521 hasConceptScore W2010426521C2522874641 @default.
• W2010426521 hasConceptScore W2010426521C2779005923 @default.
• W2010426521 hasConceptScore W2010426521C2779261636 @default.
• W2010426521 hasConceptScore W2010426521C32611913 @default.
• W2010426521 hasConceptScore W2010426521C71924100 @default.
• W2010426521 hasConceptScore W2010426521C86803240 @default.
• W2010426521 hasConceptScore W2010426521C8891405 @default.
• W2010426521 hasIssue "9" @default.

• next